Fig. 6

a KMS-11 cells were treated with the indicated combinations of siRNA. After 24 h, the percent cell death was determined and normalized to cells not treated with siRNA. Error bars show the mean of triplicate samples with SEM. b Western blot analysis of KMS-11 cells (expressing Bcl-2 to prevent death) treated with the indicated concentrations of dexamethasone (dex) in the presence of 40 μM zVAD-fmk for 48 h. c Western blot analysis of KMS-11 cells treated with Bim siRNA (siBim) or control (scrambled non-targeting) siRNA (siCtl) in the presence or absence of 100 nM dexamethasone for 72 h, and probed with antibodies against Bim and GAPDH (left panel). Cell death normalized to control siRNA (siCtl) was determined on the same samples (right panel). Error bars show the mean with SEM. d KMS-11 cells were pre-treated with dex for 72 h followed by exposure to obatoclax for 48 h. Viability for the combination treatments is expressed relative to samples without obatoclax in each dex dose group. Error bars represent the SD of triplicate samples. The table shows combination indices (CI) at the indicated concentrations of dex, calculated using COMPUSYN V.1.0 software according to the original method from Chou and Talalay [23]. e As in (D) except that viability was determined in the presence of control (siCtl) or siBim